 PR are involved in breast cancer growth. The antiprogestin mifepristone MFP exerts antitumor effects in mammary carcinomas with high expression of PRA. The investigators hypothesize that breast cancers with higher levels of PRA than PRB will benefit from an antiprogestin therapy. 